Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 492 (CSE: $FTRP.C) (CSE: $CURA.C) (TSX: $WEED.TO) (NYSE: $CGC) (OTC: $HEMP)
Delta, Kelowna, BC, November 6, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
today’s podcast we will be looking at a few public announcements and these
relate to current market trends created from new state legalization.
Trip Health Ltd. (CSE: FTRP), one of the leaders in the
development and delivery of psychedelic therapies, announced today that it is in advanced stages
of identifying potential sites for Field Trip Health centers to treat people in
Oregon with psilocybin therapies following the passage of Measure 109.
Measure 109, which was approved by
voters in Oregon on November 3, 2020, requires the Oregon Health Authority to
create a licensing system that will create a regulated program for the
cultivation of psilocybin-producing mushrooms and the provision of supervised
psilocybin therapy, effectively creating the first legal market for psilocybin
therapies in North America.
Field Trip, which has been
cultivating twenty-five species and strains of psilocybin-producing mushrooms
at its research facility at the University of West Indies (Mona) in Jamaica
since January, also announced its intention to seek licenses for cultivation in
the State of Oregon when regulations following from Measure 109 are
“Based on its geography and climate,
Oregon is an ideal place for cultivation of psilocybin-producing mushrooms. But
cultivation that meets all quality standards and analytical testing
requirements is complex,” said Marshall Tyler, Field Trip’s Director of
Research. “Our current cultivation research, which is focused on developing
safety methods for microbial contamination, pesticides, mycotoxins, heavy
metals, and analyzing tryptamine content from all psychoactive species at all
stages of growth, positions us well to establish effective cultivation
operations in Oregon and, subject to the regulations that are established, to
be able to offer a wide variety of products and therapies to the people in
Studies from institutions such as
Johns Hopkins University, New York University and Imperial College London have
demonstrated that psilocybin therapy, when performed by qualified
professionals, can have profoundly positive effects on treating mental and emotional
health challenges such as depression, anxiety, end of life distress and
addiction. Similar studies have demonstrated that psychedelic therapies may
also increase a person’s creativity, empathy, openness to others viewpoints and
regard for the environment and planet.
“From the earliest days at Field
Trip, we built our business case on the belief that the psychedelic industry
would develop on two parallel and complementary paths: one that would be purely
medical for the treatment of diagnosed mental health conditions, and the other
which would make psychedelic therapies available to a wider audience,” said
Ronan Levy, Executive Chairman of Field Trip Health Ltd. “The success of
Measure 109 validates that belief, and positions us to be the clear leader in
the emerging psychedelics industry. With Field Trip Health centers rolling out
across North America delivering best-in-class psychedelic therapies, and our
research on cultivation of psilocybe, we are extremely well-positioned to help
Oregonians access best-in-class psilocybin therapies. And with our drug
development work on FT-104, our novel psychedelic molecule, advancing ahead of
schedule, we are also positioned to help extend the psychedelic renaissance to
people around the world."
Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading vertically integrated
cannabis operator in the United States, today announced a pair of planned asset
divestitures in Maryland for a combined $31.5 million in total proceeds:
into Definitive documentation to sell Curaleaf's interests in HMS cultivation
and processor for $27.5 million to TerrAscend Corp. ("TerrAscend")
(CSE:TER, OTCQX: TRSSF)
of its sale of Cumberland, MD processor for $4.0 million
Curaleaf announced today the signing
of a definitive agreement to sell its rights to the HMS Health LLC and HMS
Processing LLC ("HMS") assets in Maryland to TerrAscend for a total
consideration of $27.5 million. The HMS asset sale includes the divestiture of
operations in a 22,000 square foot co-located cultivation and processing
facility in Frederick, MD. The total consideration due to Curaleaf of $27.5
million includes $25 million in cash due at closing as well as a $2.5 million
interest bearing Note due and payable to Curaleaf on April 30, 2022. The
transaction is expected to close pending customary closing conditions,
including regulatory approval by the Maryland Medical Cannabis Commission.
The completion of the HMS
transaction will allow Curaleaf to move forward, subject to regulatory
approval, with its proposed acquisition of Maryland Compassionate Care and
Wellness, LLC ("MCCW"), which operates a 55,000 square foot
co-located cultivation and processing facility in Taneytown, MD and a dispensary
in Gaithersburg, MD under the Herbology brand.
Curaleaf also announced today the
closing of its sale of Curaleaf Maryland, Inc., which holds a processing
license in Cumberland, MD, for a total consideration of $4.0 million. This
divestiture closed on November 1, 2020 and supports Curaleaf's strategy for
optimizing its vertically integrated presence in Maryland.
Joseph Lusardi, Chief Executive
Officer of Curaleaf, stated, "The asset sales we announce today will allow
us to optimize Curaleaf's vertically integrated presence in Maryland within the
regulation which limits operators to a single grow and single processor.
Overall, the Maryland market continues to see impressive growth with over
115,000 certified cannabis patients. The actions we are taking aim to further
strengthen Curaleaf's position as a leading cannabis operator in Maryland as
well as reaffirm our commitment to best serving our customers across the
Growth Corporation (TSX:WEED) (NYSE:CGC), a world-leading diversified
cannabis, hemp, and cannabis device company, announced the launch of Quatreau, a new line
of premium CBD-infused beverages. The naturally flavoured sparkling waters are
Canopy Growth's first CBD-infused drinks, with both CBD-only and
"balanced" (CBD + THC) offerings available in Canada. Launched on the
heels of incredible growth in sales from the Company's THC-infused beverages,
released earlier this year, Canopy Growth is uniquely positioned to win market
share in the CBD beverage space.
"We are proud to debut our
first CBD-infused beverage brand in Canada, where we already lead the
cannabis-infused beverage category, at a price point that delivers both quality
and value to consumers," said David Klein, CEO, Canopy Growth. "We created Quatreau as an alternative
to sugary, caffeinated beverages or even alcohol. With both CBD-only and "balanced"
(CBD + THC) offerings in four natural flavours, Quatreau meets the needs of
discerning cannabis consumers."
Canopy Growth plans to continue
developing category leading brands that are driven by consumer insights,
product-focused, with industry leading scientific formulation. Building on the
successful launch and strong sales of THC-infused cannabis beverage brands
Tweed, Houseplant and Deep Space, Canopy is poised to continue leading the
cannabis space with the launch of Quatreau CBD-infused sparkling water, a
consistent CBD product in a beverage format that is familiar to consumers.
Quatreau's naturally flavoured
Canadian product line includes four offerings named:
Cucumber + Mint (contains 20 mg of CBD and < 1 mg of THC)
Passion Fruit + Guava (contains 20 mg of CBD and < 1 mg of THC)
Ginger + Lime (contains 2 mg of CBD and 2 mg of THC)
Blueberry + Açai (contains 2 mg of CBD and 2 mg of THC)
Canopy was also among this week’s
large LP winners when it came to the markets, trading up nearly 5% over the
past three days and joining other winners such as Aurora Cannabis (TSX: ACB) (NYSE: ACB), which traded up nearly 70% over
the past three days, Aphria Inc. (NASDAQ: APHA) (TSX: APHA), trading up 5% and Tilray Inc. (NASDAQ: TLRY) which traded up nearly 30%.
(OTC: HEMP) a global leader in the industrial
hemp industry with bi-coastal processing centers, announced praise of five states that will now
legalize marijuana for recreational and/or medical use.
Bruce Perlowin, CEO of Hemp, Inc.,
55-year veteran of the marijuana industry, now known as the King of Hemp says,
“Marijuana is coming full circle, but legally now. Back in my heyday, I was (and still) widely
known as the King of Pot so it’s interesting to see how things have progressed
over the years and exciting to see where we’ll be in the future.”
“Hemp, Inc. is planning to launch a
new division, Medical and Recreational
Marijuana,” says Perlowin. Thus far,
there are no firm plans on what direction the Company will take in this new
planned division since the opportunities are so vast. According to Perlowin, he will evaluate all
the lucrative, potential opportunities and make a decision on how the company
will enter the cannabis market in 2021.
“We may wait until full federal
legalization. Once marijuana is fully legalized across the country, I think
banks and merchant account providers will be more open and accepting of
marijuana companies. Right now, the banking regulations for marijuana companies
are very draconian. I’ve known so many banks to close accounts merely because
they were associated with the industry. Anyway, we don’t know if we’ll wait for
full legalization yet but that decision won’t discount the building out of
facilities and preparation for it. After
legalization occurs and large scale marijuana grows are underway, we would
already be positioned as a ‘go-to’ consultant due to our industry expertise.”
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks
and other ideas on our site using our list of
top stock trading apps including
Robinhood, Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
Follow us on Twitter https://twitter.com/Investorideas
us on Facebook https://www.facebook.com/Investorideas
us on YouTube https://www.youtube.com/c/Investorideas
our Mobile App for
iPhone and Android
our Investor Club https://www.investorideas.com/membership/